| Adalimumab (N = 45) | Etanercept (N = 44) | Ustekinumab (N = 32) | Infliximab (N = 22) | |
|---|---|---|---|---|
| Cost per patient based on the doses prescribed | €4,777.06 | €4,722.38 | €5,337.34 | €6,546.82 |
| Cost per patient based on its label doses | €6.245.72 | €5.788.19 | €5,689.02 | €6,546.82 |
| Proportion of patients with PASI75 | 98% | 90% | 90% | 100% |
| Estimated annual real costs per responder | €9,771.27 | €10,389.24 | €11,778.95 | €13,093.65 |
| Estimated TC | €12,491.44 | €11,576.38 | €11,378.05 | €13,093.65 |
| Estimated RC | €9,554.13 | €9,444.76 | €10,674.68 | €13,093.65 |
| IC | €-2,937.30 | €-2,131.62 | €-703.36 | 0€ |